| Entry |
|
|---|
| Name |
HGF-overexpression to PI3K signaling pathway
|
|---|
| Definition |
HGF* -> MET -> GAB1 -> PI3K -> PIP3 -> AKT -| BAD |
|---|
| Expanded |
3082v1 -> 4233 -> 2549 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -| 572 |
|---|
| Class |
|
|---|
| Type |
Variant
|
|---|
| Pathway |
|
|---|
| Disease |
| H00048 | Hepatocellular carcinoma |
|
|---|
| Gene |
| 3082 | HGF; hepatocyte growth factor |
| 4233 | MET; MET proto-oncogene, receptor tyrosine kinase |
| 2549 | GAB1; GRB2 associated binding protein 1 |
| 5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| 5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| 207 | AKT1; AKT serine/threonine kinase 1 |
| 208 | AKT2; AKT serine/threonine kinase 2 |
| 10000 | AKT3; AKT serine/threonine kinase 3 |
| 572 | BAD; BCL2 associated agonist of cell death |
|
|---|
| Variant |
3082v1 (HGF*) HGF overexpression
|
|---|
| Metabolite |
| C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
|---|
| Reference |
|
|---|
| Authors |
Breuhahn K, Longerich T, Schirmacher P |
|---|
| Title |
Dysregulation of growth factor signaling in human hepatocellular carcinoma. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Harding JJ, Abou-Alfa GK |
|---|
| Title |
Systemic therapy for hepatocellular carcinoma. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Parikh RA, Wang P, Beumer JH, Chu E, Appleman LJ |
|---|
| Title |
The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Lee D, Sung ES, Ahn JH, An S, Huh J, You WK |
|---|
| Title |
Development of antibody-based c-Met inhibitors for targeted cancer therapy. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
